Sotrovimab Effective At Preventing Severe COVID-19 Outcomes During Omicron Period, Study Finds

Infectious Disease Advisor (6/12, Kuhns) reports, “Sotrovimab was found to be continuously effective in preventing severe clinical outcomes in patients with COVID-19 infection during the periods of Omicron BA.2 and BA.5 subvariant predominance, according to study results published in Infection.” In the study, “compared with no monoclonal antibody treatment, sotrovimab recipients exhibited lower risks in both March 2022 (adjusted relative risk [aRR], 0.36; 95% CI, 0.23-0.56; P <.001) and April 2022 (aRR, 0.32; 95% CI, 0.04-2.38; P =.0519). The risk for progression to severe, critical, or fatal COVID-19 infection was also lower among high-risk patients who received sotrovimab during the Omicron period (adjusted odds ratio, 0.88; 95% CI, 0.16-4.89).”